KemPharm, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- KemPharm, Inc. (KMPH), now operating as Zevra Therapeutics, Inc., is a commercial-stage rare disease therapeutics company focused on the discovery, development, and commercialization of proprietary prodrugs and innovative therapies addressing unmet needs in neurological, sleep, and metabolic disorders using its proprietary Ligand Activated Therapy (LAT) platform; core products and pipeline candidates include the approved commercial therapies MIPLYFFA (arimoclomol) for Niemann-Pick disease type C, OLPRUVA (sodium phenylbutyrate) for urea cycle disorders, and royalties from the partnered AZSTARYS (serdexmethylphenidate and dexmethylphenidate) for ADHD; late-stage assets encompass KP1077 (serdexmethylphenidate) in Phase 2/3 for idiopathic hypersomnia and narcolepsy, celiprolol in Phase 3 for vascular Ehlers-Danlos syndrome, and earlier-stage programs like osanetant for prostate adenocarcinoma; the company serves patients, physicians, and advocacy groups primarily in the United States and Europe with operations supporting clinical trials and commercialization. Founded in 2006 and headquartered in Celebration, Florida, with additional facilities in Coralville, Iowa, and Blacksburg, Virginia, KemPharm rebranded to Zevra Therapeutics in February 2023 to emphasize its rare disease focus following the May 2022 acquisition of arimoclomol from Orphazyme; recent developments include the November 2023 completion of the Acer Therapeutics acquisition adding OLPRUVA and EDSIVO (celiprolol), FDA approval and U.S. launch of MIPLYFFA in 2024 with EMA marketing authorization application submitted in July 2025, sale of a rare pediatric disease priority review voucher for $150 million in February 2025, expanded partnership with Corium for AZSTARYS consultations, and ongoing Phase 3 enrollment for celiprolol under FDA Special Protocol Assessment with Orphan Drug and Breakthrough Therapy designations.
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating
KemPharm, Inc. (KMPH) Q3 2022 Earnings Call Transcript
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2022 Results - Earnings Call Transcript
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2022 Results - Earnings Call Transcript
KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q4 2021 Results - Earnings Call Transcript
KemPharm to Report Fourth Quarter and Full-Year 2021 Results
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
Implied Volatility Surging for KemPharm (KMPH) Stock Options
KemPharm's (KMPH) CEO Travis Mickle on Q3 2021 Results - Earnings Call Transcript
KemPharm to Report Third Quarter 2021 Results
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market